RestoreBio

175 - The biology of aging, rapamycin, and other interventions that target the aging process

Peter Attia MD

The company conducting clinical trials for RTB 101 to gain FDA approval, which terminated its phase 3 trial early due to not hitting endpoints and subsequently merged with a cancer company.